News & Events
Webcast: Crinetics Pharmaceuticals to Report Fourth Quarter 2025 Financial Results
Event Date: February 26, 2026
READ MORECrinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
Crinetics announced that it will report fourth quarter and full year 2025 financial results on Thursday, February 26, 2026 after the market closes.
READ MORECrinetics Initiates Phase 2/3 Pediatric Trial Evaluating Atumelnant in Congenital Adrenal Hyperplasia (CAH)
Crinetics announced that the first patient has been dosed in the BALANCE-CAH Phase 2/3 trial evaluating investigational candidate atumelnant, a novel, once-daily oral adrenocorticotropic hormone (ACTH) receptor antagonist candidate for the proposed treatment of classic congenital adrenal hyperplasia (CAH) in children and adolescents.
READ MORECrinetics to Participate in the 44th Annual J.P. Morgan Healthcare Conference
Event Date: January 13, 2026
READ MORECrinetics Pharmaceuticals Announces January 2026 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Crinetics Pharmaceuticals, Inc. today announced that on January 10, 2026, the Compensation Committee of the Board of Directors granted non-qualified stock option awards to purchase an aggregate of 37,575 shares of its common stock and granted an aggregate of 25,525 restricted stock unit (“RSU”) awards to 10 new non-executive employees.
READ MORECrinetics Pharmaceuticals Announces Pricing of Public Offering of Common Stock
Crinetics announced the pricing of an underwritten public offering of 7,620,000 shares of its common stock at a price to the public of $45. 95 per share. All of the shares to be sold in the offering are to be sold by Crinetics.
READ MORECrinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock
Crinetics announced that it intends to offer and sell, subject to market and other conditions, $350 million of shares of its common stock in a proposed underwritten public offering. In addition, Crinetics intends to grant the underwriters a 30-day option to purchase up to an additional $52. 5 million of shares of common stock.
READ MORETransforming Endocrine Disease Treatment
Be the first to know about the advances we're making in endocrine-rooted care.
Email Signup
Please click CONTINUE below to learn more about a new treatment option. This website contains information about a prescription medicine.
